Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a leader in longevity research, is pleased to announce a significant grant of €381,434 from the Government of Wallonia to support its innovative Sarcopenia research program, in collaboration with Revatis SA. This grant will fund the development of muscle progenitor cells enhanced with Genflow’s proprietary SIRT6 gene, targeting the prevention and treatment of age-related muscle degeneration. CEO Dr. Eric Leire expressed the company’s commitment to improving life quality for older adults by addressing the challenges of sarcopenia.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
